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Abstract
Background: 25-hydroxyvitamin D deficiency is associated with COPD and increased susceptibility to infection in
the general population.
Methods: We investigated whether COPD patients deficient in 25-hydroxyvitamin D were more likely to be
frequent exacerbators, had reduced outdoor activity and were more susceptible to human rhinovirus (HRV)
exacerbations than those with insufficient and normal levels. We also investigated whether the frequency of FokI,
BsmI and TaqIα 25-hydroxyvitamin D receptor (VDR) polymorphisms differed between frequent and infrequent
exacerbators.
Results: There was no difference in 25-hydroxyvitamin D levels between frequent and infrequent exacerbators in
the summer; medians 44.1nmol/L (29.1 – 68.0) and 39.4nmol/L (22.3 – 59.2) or winter; medians 24.9nmol/L (14.3 –
43.1) and 27.1nmol/L (19.9 – 37.6). Patients who spent less time outdoors in the 14 days prior to sampling had
lower 25-hydroxyvitamin D levels (p=0.02). Day length was independently associated with 25-hydroxyvitamin D
levels (p=0.02). There was no difference in 25-hydroxyvitamin D levels between baseline and exacerbation;
medians 36.2nmol/L (IQR 22.4-59.4) and 33.3nmol/L (23.0-49.7); p=0.43. HRV positive exacerbations were not
associated with lower 25-hydroxyvitamin D levels at exacerbation than exacerbations that did not test positive for
HRV; medians 30.0nmol/L (20.4 – 57.8) and 30.6nmol/L (19.4 – 48.7). There was no relationship between
exacerbation frequency and any VDR polymorphisms (all p>0.05).
Conclusions: Low 25-hydroxyvitamin D levels in COPD are not associated with frequent exacerbations and do not
increase susceptibility to HRV exacerbations. Independent of day length, patients who spend less time outdoors
have lower 25-hydroxyvitamin D concentration.
Background
Serum concentrations of 25-hydroxyvitamin D vary with
age, race, sex, season and geographic location [1]. In its
physiologically active form 25-hydroxyvitamin D is
released into the circulation, binds to a carrier protein in
the plasma (25-hydroxyvitamin D binding protein
(DBP)) and is transported to various target organs where
it mediates its biological effects by binding to the 25-
hydroxyvitamin D receptor (VDR) [2]. Deficiency in 25-
hydroxyvitamin D results from a number of causes and
is associated with increased risk of infections including
influenza, TB and pneumonia [3]. VDR dysfunction,
linked to 25-hydroxyvitamin D deficiency, is thought to
cause a decline in innate immune function that increases
susceptibility to infections [4].
COPD is characterised by irreversible expiratory air-
flow limitation [5]. The disease is interspersed with peri-
ods of exacerbation that have important consequences
for patients and health care providers [6-10]. Exacerba-
tions are predominantly triggered by infection and the
commonest respiratory virus detected in the airways at
exacerbation is human rhinovirus (HRV) [11,12]. Some
individuals are more susceptible to developing exacerba-
tions and these individuals are termed “frequent exacer-
bators” [13]. Frequent exacerbators have worse quality of
life [6], greater limitation of their daily activity, spend
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[8,15,16] and greater airway inflammation [17] and
increased mortality [18] compared to patients with infre-
quent exacerbations.
Exacerbations are approximately 50% more likely in
the winter [19]. It has been postulated that humans
have improved innate immunity in the summer,
impaired in the winter and that with 25-hydroxyvitamin
D synthesis being so dependent on sunlight exposure,
falling winter levels may trigger immune deficiencies
[20]. It has also been shown recently that vitamin D de-
ficiency is associated with increased mortality in
patients admitted to hospital with community acquired
pneumonia [21] and it is possible that vitamin D defi-
ciency in COPD may increase susceptibility to pneumo-
nia at the time of exacerbation. Genetic variants in the
25-hydroxyvitamin D pathway have been associated
with chronic obstructive pulmonary disease (COPD)
[22-26] and many polymorphisms in the VDR gene [27]
have been linked with infection.
Our London COPD cohort, a well characterised group
of patients allows us to study various aspects of 25-
hydroxyvitamin D deficiency on COPD. We hypothe-
sised that with exacerbations peaking in the winter/early
spring when 25-hydroxyvitamin D levels are at their
lowest, this deficiency in 25-hydroxyvitamin D may in-
crease exacerbation risk via changes in airway inflamma-
tion. As our primary outcome we investigated whether
COPD patients deficient in 25-hydroxyvitamin D were
more likely to be frequent exacerbators. We also investi-
gated whether they had reduced outdoor activity, and
were more susceptible to HRV at exacerbation than
those with insufficient or normal levels. We investigated
whether 25-hydroxyvitamin D levels correlated with
HRV load. We also investigated whether the frequency
of VDR polymorphisms differed between frequent and
infrequent exacerbators.
Methods
Patient recruitment
Ninety seven COPD patients were studied between 1
st
April 2006 and 30
th March 2009. The recruitment and
monitoring of patients in the London COPD cohort has
previously been described [6,8,11,12,14,17]. This study
was approved by the Royal Free Hospital Research Ethics
Committee (Ref: 05/Q0501/126) and patients gave writ-
ten informed consent.
All patients had COPD as defined by a forced expira-
tory volume in one second (FEV1)o f≤80% and FEV1 to
forced vital capacity (FVC) ratio below 70% with β2
agonist reversibility of less than 15% or 200ml. Patients
were excluded if they had other significant respiratory
diseases. Patients were recruited when stable, with no
exacerbations reported in the preceding month.
At the initial visit, daily respiratory symptoms,
smoking history, drug history and co-morbidities were
recorded. Height and weight were measured along
with baseline lung function using a volumetric storage
spirometer (Vitalograph 2160, Maids Moreton, Buck-
ingham, UK). Blood was collected for 25-
hydroxyvitamin D assay. Summer samples were taken
in June, July or August, and winter samples in January,
February or March. Both samples were collected in each
individual in the same 12 month period. In each pa-
tient, spontaneously produced sputum when available
and a nasopharyngeal swab (NPS) were collected for
HRV detection.
Exacerbations
COPD patients completed daily diary cards, recording
any increase in daily respiratory symptoms. They were
asked to contact the study team if they experienced an
increase in their symptoms and were usually reviewed
within 24 hours. Major symptoms were increased dys-
pnoea, sputum volume or sputum purulence and
minor symptoms increased cough, wheeze, sore throat
or coryzal symptoms. Exacerbations were defined
according to our previously validated criteria of two
symptoms (at least one major) for two consecutive
days, or if in the opinion of the attending clinician, the
patient had an exacerbation [17]. Our exacerbation
definition has been validated against changes in quality
of life [6], inflammatory markers [17], and FEV1 de-
cline [8]. All exacerbations in this study were treated
with antibiotics and steroids. None of the exacerba-
tions required hospitalisation.
At an exacerbation visit information was collected
on symptom type. The end of the exacerbation was
taken as the last day on which lower airway symp-
toms were recorded. Spirometry was performed and
blood taken for 25-hydroxyvitamin D assay. Sputum
was collected if spontaneously produced and a NPS
taken. All exacerbations were treated with bronchodi-
lators, antibiotics and/or oral steroids as judged by the
clinician. All samples were taken prior to the initiation
of treatment. Exacerbation visits were not limited to
summer or winter months and results were adjusted
for seasonality.
Exacerbation frequency
Exacerbation frequency was determined from diary
cards. Patients were defined as ‘frequent exacerbators’ if
they had three or more exacerbations per year, or ‘infre-
quent exacerbators’ if they had less than three exacerba-
tions per year [28,29]. 3 exacerbations were chosen as
both treated and untreated exacerbations were included
in our definition.
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At the end of each day, patients record on diary cards
the number of hours they have spent out of the house
that day. The time outdoors for baseline and exacerba-
tion visits was calculated as the average time spent out-
doors in the 14 days preceding the clinic visit.
Daylength data were obtained from Meteorological
Office data (at Heathrow Airport, London) on the day
of the visit to clinic.
Patient blood sampling
Seven millilitres of venous blood collected at baseline
and exacerbation visits was centrifuged at 224 x g for 10
minutes at 4°C within two hours of collection. The
serum was then separated and stored at −80°C for later
analysis.
25-hydroxyvitamin D measurement
Samples were assayed using the LIAISON 25-OH 25-
hydroxyvitamin D TOTAL (DiaSorin, Italy). The LI-
AISON 25-OH 25-hydroxyvitamin D TOTAL is a fully
automated antibody-based two-step direct competitive
chemiluminescence immunoassay (CLIA) in the clinical
biochemistry department at the Royal Free Hospital. The
assay recognises 100% 25-OH 25-hydroxyvitamin D2
and 25-OH 25-hydroxyvitamin D3 using magnetic
micropeptide separation. The limit of detection is≤4.0
ng/ml. 25-hydroxyvitamin D deficiency was defined as
<25nmol/L, insufficiency 25 – 75nmol/L and sufficiency
>75nmol/L (conversion factor of 2.5 for nmol/L from
ng/ml). We chose to measure 25-hydroxyvitamin D as
there is a standardised assay for measurement which is
widely used and previously published on. The serum
concentration of 25-hydroxyvitamin D is typically used
to determine vitamin D status as it reflects vitamin D
produced in the skin as well as that acquired from the
diet, and has a fairly long circulating half-life.
Virus detection in NPS and sputum
Samples were collected and processed according to our
previously published methodology [28]. Briefly, patients
were instructed to blow their nose prior to the swab
being passed gently through the nose towards the
posterior nasopharynx. The swab was rotated 5–6 times
and allowed to remain in place for 5 seconds. The swab
was then immediately placed in an eppendorf containing
0.5ml PBS (phosphate buffered saline) and stored at
−80°C until RNA extraction. Sputum samples were
examined as soon as possible and within two hours of
collection. The sample was separated from contaminat-
ing saliva and processed using previously published
methods [30].
RNA was extracted from NPS using the High Pure
Viral RNA kit (Roche) according to manufacturer
instructions. RNA was extracted from sputum using Tri-
reagent LS (Sigma) according to the manufacturer
instructions. cDNA was prepared using the High-
Capacity cDNA Reverse Transcription Kit (Applied Bio-
systems) following the manufacturer instructions. Real-
time PCR was performed using the ABI Prism 7500 Real
Time PCR System (Applied Biosystems). 25μl reaction
volumes were set up (12.5μl QuantiTect Probe PCR
Master Mix (ROX reference dye, Qiagen), 1μl forward
and reverse primers (20μM), 0.35μl probe (20μM), 2.5μl
template and 7.65μl RNase free water. PCR conditions:
95°C 15 min, 40 cycles of 95°C 15 sec and 58°C 80 sec.
This methodology has been published previously [28].
Genotyping
Venous blood samples (10-20ml) were taken in EDTA
tubes at the initial visit for all patients and control sub-
jects and stored at −80°C prior to DNA extraction. DNA
extraction was performed using a Gentra
W systems Pure-
gene
W genomic DNA purification kit (Qiagen Cat no.
158389) following the Whole-Blood-Enhanced Product-
ivity protocol supplied by the manufacturer. The primers
and PCR conditions are given in Table 1.
The specific VDR polymorphisms chosen were based
on previous published literature as they are associated
with functionality.
FokI PCR
The reaction consisted of 12.5μl PCR master mix,
1.0μl Forward primer, 1.0μl Reverse primer, 8.0μl water
and 2.5μl DNA. PCR machine conditions; denaturation
94°C for 5 minutes, then 40 cycles of denaturation 94°
Table 1 Primers for VDR polymorphisms
PCR Forward primer Reverse primer
VDR AGCTGGCCCTGGCACTGACTCTGCTCT ATGGAAACACCTTGCTTCTTCTCCCTC
FokI
VDR GGGACGATGAGGGATGGACAGAGC GGAAAGGGGTTAGGTTGGACAGGA
TaqI
VDR AACTTGCATGAGGAGGAGCATGTC GGAGAGGAGCCTCTGTCCCATTTG
BsmI
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72°C 30 seconds. The final extension was at 72°C for
5 minutes.
Taq1α PCR
The reaction consisted of 12.5μl PCR master mix,
1.0μl Forward primer, 1.0μl Reverse primer, 8.0μl water
and 2.5μl DNA. PCR machine conditions; denaturation
94°C for 5 minutes, then 40 cycles of denaturation 94°
C for 30 seconds, annealing 66°C 30seconds, extension
72°C 30 seconds. The final extension was at 72°C for
5 minutes.
BsmI PCR
The reaction consisted of 12.5μl PCR master mix, 1.0μl
Forward primer, 1.0μl Reverse primer, 8.0μl water and
2.5μl DNA. PCR machine conditions; denaturation 94°C
for 5 minutes, then 30 cycles of denaturation 94°C for
30 seconds, annealing 56°C 30seconds, extension 72°C
30 seconds. The final extension was at 72°C for 5
minutes.
All PCR products were run on a 2% agarose gel with a
PCR low ladder. The gel was run at 100mV for 15 min-
utes (Horizon 58, Biometra).
VDR FokI RFLP
To genotype the samples for the FokI polymorphism
(rs2228570), a RFLP analysis was carried out by using
the FokI restriction endonuclease enzyme (R0109S New
England BioLabs). The reaction consisted of; 2μl buffer,
7.5μld H 2O, 0.5μlR E( FokI) and 10μl PCR template. The
reaction digested at 37°C for 3 hours on PCR machine.
The product was run on a 3% agarose gel. This resulted
in the following bands; FF 265bp, Ff 265, 196 and 69bp,
ff 196 and 69bp.
VDR TaqIα RFLP
To genotype the samples for the TaqIα polymorphism
(rs731236), a RFLP analysis was carried out by using the
TaqIα restriction endonuclease enzyme (R0149T New
England BioLabs). The reaction consisted of; 2μl buffer,
0.2μl BSA, 7.7μld H 2O, 0.1μlR E( TaqIα) and 10μlP C R
template. The reaction digested at 65°C for 3 hours on
PCR machine. The product was run on a 3% agarose gel.
This resulted in the following bands; TT 495bp, Tt 495,
290 and 205bp, tt 290 and 205bp.
VDR BsmI RFLP
To genotype the samples for the BsmI polymorphism
(rs1544410), a RFLP analysis was carried out by using
the BsmI restriction endonuclease enzyme (R0134S New
England BioLabs). The reaction consisted of; 2μl buffer,
7.75μld H 2O, 0.25μlR E( BsmI) and 10μl PCR template.
The reaction digested at 65°C for 3 hours on PCR
machine. The product was run on a 3% agarose gel. This
resulted in the following bands; BB 813bp, Bb 813, 670
and 145bp, bb 670 and 145bp.
Statistical analysis
Data were analysed using SPSS version 15 or STATA 8.2
(Stat Corporation, Texas, USA). The Kolmogorov-
Smirnov test of normality was applied. Normally distrib-
uted data were expressed as mean and standard devi-
ation (SD), skewed data as median and interquartile
range (IQR). Spearman rank was used to assess non-
parametric correlations. Wilcoxon and Mann Whitney U
tests were used for paired and unpaired non-parametric
tests respectively. Adjustment for seasonality and inves-
tigation of exacerbation and baseline 25-hydroxyvitamin
D levels was done using year period sine and cosine
terms. Results were therefore adjusted for repeated mea-
sures. The study was powered at 0.90 at a 2-sided 0.05
significance level to detect a difference in 25-
hydroxyvitamin D of 10nmol/L between frequent and in-
frequent exacerbators. This study was powered for the
primary outcome.
Results
Baseline patient characteristics
Ninety seven COPD patients were studied, 61 male and
36 female. The patients had a mean FEV1 of 1.19 l or
50.3% predicted. Ten COPD patients were on 25-
hydroxyvitamin D supplementation (Calcichew D3), and
were not included in the following analysis unless other-
wise stated. Each tablet of calcichew D3 contains 10
micrograms of colecalciferol and patients usually take 2
a day. The baseline characteristics are reported in
Table 2.
Table 2 Baseline Characteristics of 97 patients
COPD patients (n=97)Mean (SD)
Age (years) 71.8 (8.8)
FEV1 (litre) 1.19 (0.54)
FEV1 (% predicted) 50.3 (19.7)
FVC (litre) 2.5 (0.84)
BMI (kgm
-2) 27.0 (6.0)
Pack years smoking 50.7 (34.2)
SpO2 (%) on air 95 (2)
25-hydroxyvitamin D nmol/L Median (IQR)
Summer 41.3 (26.8 – 64.8)
Winter 27.8 (19.4 – 44.4)
Number (%)
Male 61 (62.9)
Frequent exacerbators 28 (28.9)
Current smokers 25 (25.8)
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COPD
COPD patients had lower 25-hydroxyvitamin D levels in
winter compared to summer; medians 26.7nmol/L (IQR
17.8 – 41.2) and 39.6nmol/L (26.4 – 62.9); p<0.001. With-
in individuals, summer and winter 25-hydroxyvitamin
D levels varied by 10% monthly and by 50% between
summer and winter, with summer levels being higher.
Patients taking Calcichew D3 did not show the same
significant seasonal variation in 25-hydroxyvitamin D
levels; winter median 58.1nmol/L (35.2 – 69.6), summer
median 56.2nmol/L (33.9 – 73.1; p>0.05. The seasonal
difference in 25-hydroxyvitamin D levels between these
patients is illustrated in Figure 1. There were no differ-
ences in summer 25-hydroxyvitamin D levels between
current smokers and ex-smokers, medians; 45.5nmol/L
(27.4 – 63.3) and 40.3 nmol/L (26.7 – 66.3) or winter 25-
hydroxyvitamin D levels; medians 27.0 nmol/L (14.6 –
47.7) and 28.0 nmol/L (19.9 – 43.7).
25-hydroxyvitamin D levels in frequent and infrequent
exacerbators
Figure 2 shows that there was no difference in 25-
hydroxyvitamin D levels between frequent exacerbators
(1/3 of the cohort) and infrequent exacerbators in the
summer; medians 44.1nmol/L (29.1 – 68.0) and
39.4nmol/L (22.3 – 59.2) or winter; medians 24.9nmol/L
(14.3 – 43.1) and 27.1nmol/L (19.9 – 37.6). The propor-
tion of patients’ deficient, insufficient and sufficient in
25-hydroxyvitamin D was the same in both frequent and
infrequent exacerbators groups. Exacerbation history
was available in a subset of 10 patients before and after
treatment with Calcichew D3. There was no difference
in actual exacerbation number from year 1 to 2; p=0.45,
or in exacerbation frequency from year 1 to 2; p=0.38.
Time outdoors and 25-hydroxyvitamin D levels
Figure 3 shows that shorter day length on the day of
sampling was associated with lower levels of 25-
hydroxyvitamin D (coef 1.65, se 0.69; p=0.02). Patients
who spent less time outdoors in the 14 days prior to sam-
pling also had lower 25-hydroxyvitamin D levels coef 2.36,
se0.96; p=0.02). This was independent of day length.
25-hydroxyvitamin D levels and exacerbations of COPD
We measured serum 25-hydroxyvitamin D levels in 58
exacerbations; 1 per patient in the study period.
Adjusting for seasonality, there was no difference in
25-hydroxyvitamin D levels between baseline and ex-
acerbation; medians 36.2nmol/L (IQR 22.4-59.4) and
33.3nmol/L (23.0-49.7); p=0.43.
25-hydroxyvitamin D and HRV exacerbations
46 exacerbations were tested for the presence of HRV in
sputum or NPS. HRV positive exacerbations (n=12, viral
load>175pfu/ml; [28] were not associated with lower
25-hydroxyvitamin D levels at exacerbation than exacer-
bations that did not test positive for HRV; medians
30.0nmol/L (20.4 – 57.8) and 30.6nmol/L (19.4 – 48.7).
HRV load in sputum or NPS at exacerbation did not
25-
hydroxyvita
min D
levels 
nmol/L
Summer Winter
p = 0.88
p < 0.001
p < 0.001  p = 0.18
On calcichew D3 (n=10)
Not on calcichew D3
(n = 87)
Figure 1 25-hydroxyvitamin D levels in COPD patients in summer and winter in those on and not on calcium and 25-hydroxyvitamin D
supplementation. Data are presented as median, with the boxes representing the interquartile range and the whiskers representing SD. ○:
extreme outliers.
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(data not shown). When including all exacerbations per
patient taken over the study period tested for HRV,
patients deficient in 25-hydroxyvitamin D at baseline did
not have an increased proportion of HRV positive
exacerbations compared to those insufficient or suffi-
cient. This is illustrated in Table 3. The presence of cold
symptoms at exacerbation was not related to vitamin D
deficiency (p>0.05).
Exacerbation length and severity
There was no relationship with 25-hydroxyvitamin D
levels either at that exacerbation or the baseline preced-
ing that exacerbation and the length of the exacerbation;
25-
hydroxy
vitamin D
Summer Winter
Infrequent exacerbators
Frequent exacerbators
p = 0.21
p = 0.64
p < 0.001
p < 0.001
Figure 2 25-hydroxyvitamin D levels in summer and winter in frequent and infrequent exacerbators. Data are presented as median, with
the boxes representing the interquartile range and the whiskers representing SD. ○: extreme outliers.
25-
Day length Hours outdoors
Figure 3 Adjusted partial residual plot of the relationship between 25-hydroxyvitamin D levels and (1) day length (hours), and (2)
hours outdoors. The graphs show the effect of each variable on 25-hydroxyvitamin D independently of the other variable. The zero value is the
annual average.
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ively or time to the next exacerbation; rho=−0.11,
p=0.66 and rho=−0.06, p=0.81 respectively. All exacer-
bations recovered.
VDR polymorphisms
All genotypes were within Hardy Weinberg equilibrium.
The FokI polymorphism was not related to TaqIo r
BsmI, however the BsmI and TaqI polymorphisms were
linked (p<0.001). There was no relationship with geno-
typing and exacerbation frequency for any of the poly-
morphisms as illustrated in Table 4.
Discussion
We have investigated several aspects of 25-
hydroxyvitamin D deficiency in a well characterised co-
hort of COPD patients and shown that independent of
day length, COPD patients who spend less time out-
doors have lower 25-hydroxyvitamin D levels. In this
study we found that patients on Calcichew D3 had much
higher levels of 25-hydroxyvitamin D than COPD
patients not on 25-hydroxyvitamin D supplementation
and showed much less seasonal variation in 25-
hydroxyvitamin D levels. This is an interesting finding as
several studies have investigated the pharmacokinetics of
25-hydroxyvitamin D, and it is thought that the amount
of cholecalciferol in Calcichew is far below the amount
required to treat deficiency and maintain a stable 25-
hydroxyvitamin D level. This suggests that perhaps these
patients may differ with respect to underlying sub-
phenotype or co-morbidities (e.g. osteoporosis). How-
ever with only 10 patients in this group it is not possible
to reach firm conclusions.
Outdoor activity and 25-hydroxyvitamin D levels
From this study it appears that 25-hydroxyvitamin D
levels are driven primarily by season and outdoor activ-
ity, with patients with lower 25-hydroxyvitamin D levels
spending less time outdoors in the 14 days preceding
sampling. This has implications for pulmonary rehabili-
tation, patient education and lifestyle modification. Inde-
pendent of 25-hydroxyvitamin D status, reduced activity
in COPD is related to poorer prognosis [31]. Perhaps
outdoor pulmonary rehabilitation should be encouraged
in those COPD patients deficient in 25-hydroxyvitamin
D.
A large proportion of the elderly population in the
USA and Europe are 25-hydroxyvitamin D deficient [32]
and those with COPD are at particularly high risk [1].
Studies in asthma linking low 25-hydroxyvitamin D
levels with disease severity have postulated the relation-
ship may be secondary to time spent indoors [33]. This
is also likely to be important in COPD [14]. 25-
hydroxyvitamin D deficiency in the COPD population
may reflect poor general health status rather than having
particular importance in the natural progression of
COPD. However, if it were that simple, patients with
COPD living in tropical countries should have milder
disease and fewer exacerbations.
25-hydroxyvitamin D levels and exacerbations and
exacerbation frequency
Patients deficient in 25-hydroxyvitamin D in the stable
state (< 25nmol/L), were not more likely to be frequent
exacerbators and did not have a shorter time to their
next exacerbation than those insufficient or sufficient in
25-hydroxyvitamin D. 25-hydroxyvitamin D levels were
unchanged between baseline and exacerbation in COPD
when adjustments were made for seasonality and we did
not find a relationship between 25-hydroxyvitamin D de-
ficiency and exacerbation severity. This is in keeping
with a recent study which found that low baseline 25-
hydroxyvitamin D levels in patients with severe COPD
did not predict subsequent exacerbations [34]. A recent
RCT has also shown that high dose vitamin D
Table 3 25-hydroxyvitamin D status and positivity for
HRV at exacerbation
25-hydroxyvitamin positive for HRV at exacerbation Total
D status No Yes
Deficient 4 (25.0%) 7 (23.3%) 11
Insufficient 10 (62.5%) 19 (63.3%) 29
Sufficient 2 (12.5%) 4 (13.3%) 6
Total 16 30 46
25-hydroxyvitamin D deficiency was defined as <25nmol/L, insufficiency
25 – 75nmol/L and sufficiency>75nmol/L (conversion factor of 2.5 for nmol/L
from ng/ml).
Table 4 VDR polymorphisms and exacerbation frequency
SNP Genotype Frequent
exacerbators
(n=28)
Infrequent
exacerbators
(n=68)
Chi squared
P value
Rs1544410 BB 3 (10.7%) 15 (22.1%)
BsmI Bb 12 (42.9%) 26 (38.2%) 0.43
Bb 13 (46.4%) 27 (39.7%)
HWE p value 0.93 0.08
(n=26) (n=66)
Rs731236 TT 10 (38.5%) 24 (36.4%)
TaqI Tt 13 (50%) 29 (43.9%) 0.64
Tt 3 (11.5%) 13 (19.7%)
HWE p value 0.69 0.43
(n=28) (n=68)
Rs2228570 FF 10 (35.7%) 21 (30.9%)
FokI Ff 14 (50.0%) 38 (55.9%) 0.87
Ff 4 (14.3%) 9 (13.2%)
HWE p value 0.80 0.21
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acerbation incidence [35]. However the authors of this
study in a post-hoc analysis suggested that in patients
with the most severe vitamin D deficiency at baseline,
supplementation may reduce future exacerbations.
Influenza and other viruses show a distinct predilec-
tion for wintertime infectivity, and exacerbations of
COPD are significantly more likely to occur in the win-
ter. 25-hydroxyvitamin D deficiency has been associated
with self-reported upper respiratory tract infections
(URTI) [36,37]. As HRV is the commonest cause of colds
and present in over 50% of COPD exacerbations, we
chose specifically to investigate a relationship between
HRV exacerbations and 25-hydroxyvitamin D defi-
ciency. We did not find a relationship between 25-
hydroxyvitamin D deficiency and the presence of HRV
at exacerbation or HRV load at exacerbation. In other
diseases, 25-hydroxyvitamin D supplementation studies
have shown mixed results with regards to preventing
viral and bacterial infections [38,39]. We did not have
bacterial culture data available in this study and were
unable to investigate any association between vitamin D
levels and bacterial exacerbations.
VDR polymorphisms
We did not find a relationship between VDR poly-
morphisms and exacerbation frequency. However, the
FokI, and TaqI Vitamin D receptor polymorphisms have
been shown to be associated with lower respiratory tract
infections in children [40]. Genetic variants in the 25-
hydroxyvitamin D pathway have been associated with
COPD [1,24]. Although GWAS studies did not find VDR
to be an important risk gene for COPD, associations of
VDR with risk for infections [40] has been found in in-
vestigating interactions between low 25-hydroxyvitamin
D levels and the VDR. Many polymorphisms exist in the
VDR gene and the influence of these polymorphisms on
VDR protein function may influence immunomodula-
tory responses [27]. To date no study has found a link
with VDR polymorphisms and airway infection in COPD
although there are several mechanisms by which acti-
vated 25-hydroxyvitamin D binding to the VDR could
modulate viral lower respiratory tract disease [41-43].
Our study was powered on the primary outcome and
our sample size for a genetic study is relatively small.
This may explain our negative findings.
There are several strengths to this study. The London
COPD cohort is a well characterised cohort of COPD
patients with detailed information on exacerbations and
exacerbation frequency. In this cohort monitoring visits
are predefined at regular time intervals and driven by
clinical visits because of exacerbations thus allowing in-
formation to be obtained on 25-hydroxyvitamin D at
baseline and exacerbation.
We do not actually know what constitutes 25-
hydroxyvitamin D deficiency, particularly in the context of
its immunomodulatory properties. In terms of calcaemic
effects, levels below 50nmol/L are probably deficient
[3,44]. With regards to the immunomodulatory mechan-
isms of 25-hydroxyvitamin D it has even been suggested
that levels>100nmol/L are needed for optimal immune
functioning. There is much to be learned about the role of
25-hydroxyvitamin D in COPD and the mechanisms by
which increasing 25-hydroxyvitamin D levels into the nor-
mal range would influence the natural history of COPD.
Conclusions
In conclusion, we have shown that independent of day
length, patients who spend less time outdoors have lower
25-hydroxyvitamin D levels. Low 25-hydroxyvitamin D levels
in COPD are not associated with exacerbation frequency
and do increase susceptibility to HRV exacerbations.
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